Quick Pitch: Apiam Animal Health (AHX:AX)

Merger Arbitrage (covered at A$0.795)

Apiam Animal Health is the last publicly traded veterinary services provider in Australia. The company has received a takeover offer from Adamantem Capital at A$0.88/share. The spread stands at 11%. The board has indicated that the proposal follows a period of engagement with Adamantem and other unsolicited interest in Apiam and that it is prepared to recommend it to shareholders if a binding agreement is reached. Adamantem has been granted 30 days of exclusivity. Due diligence is underway.

I do not think there will be any opposition from shareholders regarding this buyout. The offer comes at 10x EBITDA, 60% premium to pre-announcement prices and four-year high share price. AHX’s largest shareholder (24%) and founder, Dr. Chris Richards, is supporting the offer. Richards has also granted Adamantem a call option on 20% of shares exercisable at A$0.88/share—but only if a rival bidder appears. So a competing bid is unlikely.

A further 13% AHX stake is held by a syndicate led by Vita Pepe and Bruce Dixon, two prominent Australian business figures. Both have recently joined AHX’s board (with Dixon also appointed as an interim managing director after the founder’s resignation in June) and were most likely involved in discussions with Adamanten and in board consensus to support the offer. Their cost basis is around A$0.50/share (acquired in October 2024).

The real question/risk is whether Adamantem could walk after due diligence—in which case downside could be 30%+. I think the odds of that happening are low.

The valuation seems fair. AHX is getting acquired at 10.5x FY25 underlying EBITDA, broadly in line with precedent transactions for scaled up players in Australia:

• VetPartners (267 clinics vs. AHX’s 80) was acquired by EQT in 2023 at 11x EBITDA.
• Greencross Limited (160 vet clinics, 247 retail stores) was acquired by TPG in 2019 at 10x EBITDA. TPG then sold a 45% stake in 2022 at what was described as a “low double-digit” earnings multiple.
• National Veterinary Care (140 clinics) was acquired in 2019 at 16x EBITDA.
• CVS Group, a major vet player in UK, has recently been on an acquisition spree in Australia, buying mom-and-pop clinics at 7–8x EBITDA. The lower multiples reflect the smaller scale of those practices.
• AHX’s own acquisitions in 2020–2023 were done at undisclosed multiples, but its 2015 IPO prospectus indicated that it typically pays around 6x EBITDA.

The buyout comes on the cusp of the expected inflection in demand. Veterinary businesses in Australia have been in strong demand since 2020, when pet ownership skyrocketed. Importantly, the ownership boom is expected to translate into earnings only from FY26, when pets reach mid-life and require more frequent care. AHX’s founder summarized this industry dynamic on the FY24 call (emphasis mine):

From sort of ’26, ’27 onwards, as animals enter into that late adult stage, you would expect that revenues across those COVID pets are going to increase quite significantly. So I think everybody is looking out saying, well, there’s probably a 5- to 10-year pretty strong tailwinds in this industry once we get through the current couple of years at the lower cycle of the animal. So I think that’s why there’s probably been a lot of activity.

The buyer is likely positioning to capture this upcoming spike in demand.

The Australian vet sector is still in the early stages of consolidation, with about 90% of practices owned by small operators, many of them single-clinic businesses. AHX tried to seize that opportunity with an aggressive roll-up strategy between 2020 and 2023, but stumbled on integration and leverage issues. It had to halt M&A last year as net debt increased to 3x+ and issuing equity became uneconomic (i.e. CVS Group is now paying 7–8x EBITDA for small practices, while AHX itself was trading at 7.4x before the current bid).

Despite the setbacks with certain acquired clinics, the core vet clinics business is very stable and could easily support much more leverage under private ownership. It would not be surprising if Adamantem’s intentions are to revive the roll-up strategy, expand the number of locations, streamline the business, and then exit a few years down the line with a healthy IRR, just as the industry tailwinds begin to take hold.

Adamantem is a buyout firm with A$2bn in AUM. AHX’s enterprise value of about A$220m fits neatly with Adamantem’s typical transactions: it acquired two other companies this year for A$200m and A$250m, and recently raised its third fund (A$220m) focused on environmental opportunities. Adamantem’s portfolio also includes Hygain Holdings, a leading horse-feed producer in Australia, and there could be some synergies with the seven equine clinics operated by AHX.

So all in all, AHX seems to fit the private equity buyout playbook pretty well and it is easy to see why Adamantem might be interested in acquiring this business. I would expect the parties to sign a binding SID shortly.

 

More details on Apiam Animal Health

The company listed in 2015 at A$1/share, with 25 locations across Australia. At the time, the primary focus was on production-animal services (beef, sheep, pork, dairy cattle) for Australian farmers. Companion animals generated only 12% of revenue.

Between 2020 and 2023, management went on an M&A spree, shifting the business toward companion animals and broader clinical vet services. The portfolio expanded to 80 clinics, and clinical services (pets, equine, testing labs) now account for 75% of revenue.

The results were mixed: some clinics underperformed, EBITDA margins dropped, and the share price fell from A$1 in 2021 to A$0.30 by 2024. The roll-up was put on hold, while the company began divesting weaker clinics and looking to cut costs.

Historical financials are in the table below:

* Note: fiscal year ends in June. Pre-AASB 16 EBITDA deducts lease expenses, which are otherwise capitalized.

 

Things I couldn’t fit elsewhere

• The A$0.88/share offer price will be reduced by any dividends paid. Apiam has just declared a final FY25 distribution of A$0.01/share with an ex-dividend date on September 2.
• If the transaction proceeds, management is considering declaring a special dividend, which would also reduce the consideration accordingly.
• AHX has been a potential takeover target for a while now. Last year, rumors surfaced that AHX was being circled by multiple bidders. The company confirmed that it had received a non-binding offer (price undisclosed), which was unanimously rejected as undervaluing. At the time, the stock was trading roughly in line with the recent pre-announcement levels.
• Adamantem got 30 days exclusivity. Interestingly, the first 20 days are “hard exclusivity”, which unlike the standard version, includes a “no fiduciary out” clause. This restricts directors from engaging with rival bidders even if a superior offer emerges. While not allowed in the US, this practice is permitted in Australia in certain circumstances. Still, it remains controversial and often resisted by boards. I suppose that the fact AHX agreed with it suggests it views Adamantem’s bid as both credible and likely to advance.
• this April. Just weeks later, Pepe and Dixon (long-time associates who have sat on multiple boards together) joined AHX. Two months after that, Adamantem lobbed its offer.